NTLA Q3 2025 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+51.3% YoY

Gross Profit

-$65M-472.8% margin

Operating Income

-$111M-808.9% margin

Net Income

-$101M-735.2% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

-3.3%

Cash Flow

Operating Cash Flow

-$77M

Free Cash Flow

-$77M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$925M

Total Liabilities

$177M

Stockholders' Equity

$748M

Cash & Equivalents

$193M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$9M	+51.3%
Gross Profit	-$65M	$9M	-815.3%
Operating Income	-$111M	-$145M	+23.0%
Net Income	-$101M	-$136M	+25.3%